Published 30 April 2021
Chemical and biological (CB) threats have become increasingly ubiquitous and diverse, presenting significant risks to soldiers in theater and stability operators during pandemic outbreaks. PPE can be bulky, heavy, and cumbersome, often severely limiting user mobility and performance. A DARPA program aims to develop technology that reduces the need for burdensome protective equipment while increasing individual protection against CB threats.
Chemical and biological (CB) threats have become increasingly ubiquitous and diverse, presenting significant risks to soldiers in theater and stability operators during pandemic outbreaks. State-of-the-art personal protective equipment (PPE) can be bulky, heavy, and cumbersome, often severely limiting user mobility and performance. The Personalized Protective Biosystem (PPB) program aims to develop technology that reduces the need for burdensome protective equipment while increasing individual protection against CB thre
/PRNewswire/ Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the SCOPE.
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
Inovio Pharmaceuticals (NASDAQ:INO) hasn t ranked among the leaders in the COVID-19 vaccine race so far. However, the small biotech has been a definite contender in the second tier of vaccine makers. Inovio hoped to separate from the pack by delivering impressive results with a planned late-stage study of its COVID-19 vaccine candidate INO-4800.
That plan just ran into a major obstacle, though. Inovio announced last Friday that the U.S. Department of Defense has decided not to fund the company s phase 3 study. The news caused the biotech stock to plunge 26%. Can Inovio recover from its huge setback?
INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company s ongoing vaccine developments for COVID-19.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.
Share this article
Share this article
PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA), will discontinue funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment. In correspondence, JPEO informed INOVIO: The decision results from the changing environment of